Kura Oncology, Inc. — Q1 2024 Form 10-Q Summary
Business context and reporting period
Kura Oncology is a clinical-stage biopharmaceutical company focused on precision oncology. The company has no approved products and has generated no product revenue. Its clinical pipeline includes ziftomenib, tipifarnib and KO-2806, supported by discovery-stage programs. This report covers the three months ended March 31, 2024, and was filed May 2, 2024.
Key financial metrics
| Metric | Q1 2024 | Q1 2023 / Prior period | Change |
|---|---|---|---|
| Product revenue | $0 | $0 | No product revenue |
| Research and development expense | $36.3 million | $25.2 million | +$11.1 million |
| General and administrative expense | $18.2 million | $11.4 million | +$6.8 million |
| Total operating expenses | $54.5 million | $36.6 million | +$17.9 million |
| Other income, net | $4.9 million | $2.5 million | +$2.4 million |
| Net loss | $49.5 million | $34.1 million | Loss increased $15.5 million |
| Net loss per share | $0.59 | $0.50 | Loss per share increased |
| Cash used in operating activities | $48.8 million | $35.9 million | Use increased $13.0 million |
| Cash, cash equivalents and short-term investments | $527.1 million | Not clearly stated in the filing excerpt | Up from $423.9 million at December 31, 2023 |
| Long-term debt, net | $9.4 million | Not clearly stated for Q1 2023 | Up from $9.3 million at December 31, 2023 |
Gross and operating margins are not meaningful because the company has no product revenue. Interest and other income increased primarily because of higher interest income on investments. Share-based compensation expense was $8.5 million, compared with $6.8 million in Q1 2023.
Material changes versus the prior comparable period
- Research and development expense increased 44%, primarily due to higher ziftomenib-related costs, including the registration-directed trial and combination studies. KO-2806 and discovery-stage costs also increased.
- Tipifarnib-related research and development expense decreased because the registration-directed tipifarnib trial had closed.
- General and administrative expense increased 60%, driven by higher personnel costs, professional services and pre-commercial planning expenses.
- Operating cash use increased as the net loss expanded and working-capital changes did not offset the higher spending.
- Investing activities used $95.3 million, primarily reflecting purchases of marketable securities, compared with $11.1 million of investing cash inflow in Q1 2023.
- Financing activities provided $148.4 million, including approximately $145.8 million of net proceeds from the January 2024 private placement and $2.6 million from equity-plan issuances.
- Common shares outstanding increased to 76.2 million at March 31, 2024 from 74.4 million at December 31, 2023. The private placement also included pre-funded warrants to purchase 7.3 million shares.
Guidance, outlook, commentary and unusual items
- Management expects the $527.1 million of cash, cash equivalents and short-term investments at March 31, 2024 to fund operating expenses into 2027 under current plans, but states that substantial additional financing will eventually be required.
- The company expects research and development and general and administrative expenses to increase as clinical development and pre-commercial activities expand.
- Management expected enrollment of the 85-patient Phase 2 KOMET-001 study of ziftomenib in relapsed or refractory NPM1-mutant AML to be completed by mid-2024.
- On April 22, 2024, after quarter-end, the FDA granted ziftomenib Breakthrough Therapy Designation for relapsed or refractory NPM1-mutant AML. The designation may support expedited interactions and review but does not assure approval.
- The company initiated dosing in additional ziftomenib sub-studies during Q1 2024, dosed the first patient in the KOMET-008 study in February 2024, and planned to identify recommended Phase 2 combination doses by mid-2024.
- For tipifarnib, management expects to complete enrollment of two KURRENT-HN expansion cohorts by the end of 2024 and anticipates presenting data in the first half of 2025.
- For KO-2806, the first patient was dosed in combination with cabozantinib in clear cell renal cell carcinoma in March 2024. The company anticipated initiating the KRAS G12C-mutant non-small-cell lung cancer cohort by mid-2024.
- The company has borrowed $10.0 million under a term-loan facility with a total potential commitment of up to $125.0 million. The draw periods for the remaining Tranche 1 amount and the $35.0 million Tranche 2 expired without additional borrowings. Up to $40.0 million under Tranche 3 may become available subject to conditions, and up to $25.0 million under Tranche 4 is subject to lender approval.
- The company has a $150.0 million at-the-market facility but had not sold shares under it as of the filing date.
- Unrealized losses on available-for-sale securities were attributed primarily to interest-rate changes rather than credit deterioration; the company reported no allowance for credit losses.
- Material risks include clinical and regulatory failure, adverse events, patient enrollment and diagnostic challenges, reliance on third-party manufacturers and collaborators, intellectual-property disputes, future financing needs and potential stockholder dilution.
Most important facts for investors to verify
- Whether ziftomenib’s Phase 2 registration-directed study meets enrollment, efficacy, durability and safety objectives and supports an NDA filing.
- The impact of competition from other menin inhibitors, including the timing and results of competing programs.
- Whether the company’s projected liquidity runway into 2027 remains achievable as clinical spending increases.
- The terms, availability and covenant requirements of the remaining term-loan tranches, including the minimum cash covenant and secured lender rights.
- The potential dilution from 10.4 million outstanding pre-funded warrants, options, restricted stock units, performance-based awards and future equity financing.
- Whether companion diagnostics, third-party drug supplies and contract manufacturers can support regulatory approval and commercialization.
- The company’s ability to obtain substantial additional capital without materially diluting shareholders or relinquishing valuable development and commercial rights.